Genmab — Maj 2016
-
Nå Lego, jeg kunne alligevel ikke lade det ligge. Der var kun ofa og dara på ASH sidste år. Ligeledes på EHA. Men på ASCO sidste år var der en TF-ADC-poster. Så vi skal ikke forvente Tisotumab på ASH 16, i så fald bliver det på Genmabs egen R&D-dag umiddelbart efter. http://ir.genmab.com/events.cfm#tab2
-
D. 25.
-
Hej,
-
Hej, hvilke selskaber/produkter er Genmabs nærmeste konkurrenter.
-
Har en normal størrelse position i Genmab, men mangler mere overblik over konkurrencesituationen for evt. at øge den. Hvor er de største trusler i de kommende år? Genmab har jo vist fremragende fremskridt, så ikke bekymret for dem
-
The following attends to the question raised by saini21:
-
.. I’m notoriously known for my ideas with regards to the nature of the collaboration between Genmab and Gilead. There could be several reasons for the omission in the Q1 report. It although remains certain that we are looking at a deliberate action and not just an unfortunate mistake leading to the omission.
-
The initial public confirmation of the existence of the partnership was likewise done in a highly controversial fashion… I pointed towards the existence of the partnership at least half a year before it was officially confirmed
-
I finally also wrote about the peculiar way that Genmab decided to quietly disseminate the confirmation of the secret partnership with Gilead
-
The partnership with Gilead represents a highly significant basis for substantiating the world class attractiveness of Genmab’s technology platforms. The partnership further represents a potential future value driver that would help to underpin our current position among the most successful biotech companies
-
A substantial commercial deal with Gilead could be instrumental in propelling us towards Jan van der Winkels vision of creating an iconic biotech company.
-
Gilead is in dire need of a pipeline boost after the recent demise of Zydelig induced by the occurrence of adverse side effects. The drug was otherwise heralded as holding the key to securing Gilead a solid foothold in oncology
-
Gilead has undisputable large-scale ambitions in oncology and Genmab has an excellent strategic fit that could help Gilead leapfrog into the arena and directly join the big players
-
It is only a short while ago that an American journalist speculated in the urgent need for partner or acquisition to realize the aggressive growth ambitions of Gilead. The CEO is under immense pressure and needs to ensure his legacy as a master dealmaker like his predecessor who literally transformed the company through the acquisitions
-
of both companies and drugs...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind